208340 — PharmAbcine Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMicro Cap

Annual cashflow statement for PharmAbcine, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2019 December 31st	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	-10,158	-30,678	-44,033	-30,548	-14,247
Depreciation
Amortisation
Non-Cash Items	534	5,560	6,759	7,978	3,600
Unusual Items
Other Non-Cash Items
Changes in Working Capital	691	2,571	-3,588	3,307	-2,334
Change in Accounts Receivable
Change in Prepaid Expenses
Change in Accounts Payable
Change in Accrued Expenses
Change in Other Liabilities
Net Change in Other Assets & Liabilities
Other Operating Cash Flow
Cash from Operating Activities	-7,230	-20,754	-39,646	-18,181	-11,948
Capital Expenditures	-1,278	-4,213	-1,176	-2,006	-79.3
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	-72,889	18,418	68,700	-4,757	9,899
Sale of Fixed Assets
Sale/Maturity of Investment
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities	-74,168	14,204	67,524	-6,763	9,820
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	97,131	-890	-28,320	-1,662	359
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	15,730	-8,473	101	-24,861	-1,464